Table 1.
The composition and characteristics of the tested niosomal formulations
| Code | Compositiona | Weight ratio | EE (%) | Zeta potential (mV) | Z-average (nm) | PDIb |
|---|---|---|---|---|---|---|
| Nio1 | S:CH | 1:1 | 91.25 ± 2.80 | − 53.06 ± 2.40 | 90.60 ± 1.90 | 0.30 ± 0.01 |
| Nio2 | S:CH | 2:1 | 94.65 ± 3.33 | − 56.75 ± 2.60 | 96.56 ± 1.87 | 0.34 ± 0.02 |
| Nio3 | S:CH | 3:1 | 92.56 ± 4.21 | − 58.10 ± 3.10 | 97.60 ± 1.55 | 0.36 ± 0.01 |
| Nio4 | S:B | 1:1 | 96.70 ± 2.30 | − 67.80 ± 3.40 | 93.56 ± 2.22 | 0.31 ± 0.01 |
| Nio5 | S:B | 2:1 | 98.22 ± 1.44 | − 65.38 ± 3.20 | 94.66 ± 2.34 | 0.33 ± 0.02 |
| Nio6 | S:B | 3:1 | 93.55 ± 1.99 | − 58.50 ± 3.00 | 98.7 ± 1.22 | 0.36 ± 0.01 |
| Placebo I | S:CH | 3:1 | – | − 25.70 ± 2.45 | 86.66 ± 1.11 | 0.28 ± 0.02 |
| Placebo II | S:B | 3:1 | – | − 24.60 ± 2.68 | 84.99 ± 1.33 | 0.27 ± 0.01 |
aS Span 60, CH cholesterol, B Brij 52
bPDI poly-dispersity index